Member Info for Willysang

Most Likely Scenario (60-70% Probability): Mid-March to early April 2026 (3-6 weeks from now).

Post-holiday backlog clearing + By-Health's strong position (first-mover for this claim, solid EFSA-backed clinicals/patents, no补正 needed reported) should push it into the next batch soon.

If a batch drops in March (common pattern for Q1 follow-ups), issuance could be "any week" thereafter.

Best Case (20-30% Probability): Early-to-mid March 2026 (within 2-4 weeks).

If queued pre-holiday and prioritized (high-profile innovation), it could appear in an imminent batch announcement

What's the endgame???

A matter of weeks...let's gooooooo

For sure it's not perfect....but it does give a good deep dive ..the analysis is best we have ...

...

Maybe 3 months max....then too the moon 🌝

What does this mean?

In China, new health foods (especially those claiming specific functions or using novel ingredients) must go through a strict registration process with the State Administration for Market Regulation (SAMR) to obtain the "blue hat" approval (official health food certification).

The approval process typically includes:

Submission of application materials

Technical review

On-site verification and/or sample testing (if required)

Final administrative approval

Entering the on-site registration verification stage is a significant positive milestone because:

It indicates that the initial technical review has been largely completed and the application materials are considered basically compliant.

Regulators will now send inspectors to the production site to verify:

Whether the actual production process matches what was declared

The authenticity of R&D and trial production records

Quality control systems and GMP (Good Manufacturing Practice) compliance

Samples may also be drawn for further testing.

The issuance of the electronic confirmation notice on December 16 formally confirms that this on-site inspection will take place.

This is usually one of the final major steps before approval:

If the on-site verification goes smoothly (which it does in the vast majority of cases unless serious issues are found),

The product is likely to receive its official health food registration certificate ("blue hat") soon,

Allowing it to be legally marketed and sold nationwide.

For By-Health, this represents an important potential new product growth driver in the highly competitive nutritional supplement market. It's a strong positive signal for the approval timeline and should boost investor confidence and potentially the stock price.

In summary: The approval process is progressing smoothly and is now in the late stages—final approval could come relatively soon. Definitely worth staying optimistic about!

From grok.....In summary, NRoute as a brand is growing rapidly and shows promise, but Heartisafe likely has modest sales—it's not a top-seller or widely reviewed yet. It's probably appealing to a targeted audience interested in patented, natural heart support ingredients. If you're considering it, check recent customer feedback on their site or consult a doctor for heart supplements

That sounds promising....simular to groks prediction...I think everyone thinks it's due ...new year could be epic!🤞

My Prediction: Timeline Forecast

Base Case (70% Probability): Approval in 4–8 months (by March–July 2026).

→ Total process: ~32–44 months. Why? Elapsed time + precedents suggest the review phase is wrapping; expect an RNS from Provexis/BYHEALTH in Q1/Q2 2026 announcing green light + product launches. This unlocks £3–5m Year 1 revenue for Provexis.

Bull Case (20% Probability): 3 months or less (by February 2026).

→ If 2025 reforms kick in hard, or holiday-season lull ends with a bang. Stock pops 50–100% on news.

Bear Case (10% Probability): 9–18+ months (into late 2026/early 2027).

→ Data tweaks or backlog. Still viable, but delays BYHEALTH launches.

Confidence Level: Medium-High. This is binary (approval likely, given investment), but timing's fuzzy. Watch for catalysts: Provexis's next trading update (likely Jan 2026) or BYHEALTH's Q4 earnings (Dec 2025, in Chinese—translatable via tools if needed).

What Triggers Action? Approval = explosive catalyst for PXS.L (re-rating to £10m–£20m market cap). Even partial wins (e.g., product OK without full claim) enable sales.

Provexis delivered a breakout year: revenue up 61% to £1.29m, driven by Fruitflow II SD (+79%). Losses narrowed 41% to £278k, cash surged to £708k (vs £189k). New EU subsidiary live, DSM partnership gaining traction with global majors, and BYHEALTH (China) advancing a multi-product launch backed by tens of millions in R&D. Post-year: inventory sold out, new batch shipped, H1 sales >£350k, Q3 several £100k’s, and 3+ production runs planned for 2026+.

Score: 8.5 / 10

Suspension never ends well... delisted..that wouldn't surprise me 🫣

21st October.... results????

Maybe they will announce the blue cap approvel during the suspension!!!! We live hope 🙏🙏

At the end of day ..I want PXS to succeed like everyone...but when there is a suspension it's always bad news... Cash cow for the management for 15+ years...jeez

Till mid October??? Holy fook

great product...****e management...2 months delay in supply..that's shocking.....pray for pxs tomorrow

Reading all the data ....it's got to be 6 months or less??

Blue cap approval is due any month now ....could be 1 or 12.

...

Blue approval is due any month now ....could be 1 or 12.

...

The registration process for health foods typically takes 2 to 3 years, but for novel claims like Fruitflow’s, it can extend to 2 to 4 years due to the complexity of establishing a new health claim. By-Health expected to complete its final study in 2022 and file the submission thereafter, but no updated confirmation of approval is available in the provided data or recent sources. Assuming the submission was filed around 2022-2023, approval could be expected between 2024 and 2026, depending on SAMR’s review pace and dossier quality